Ann: Dronabinol Supply Agreement/Sleep Apnoea Trial Update, page-48

Keep in mind dronabinol is a cannabinoid, it’s a drug not a company. In fact dronabinol was the first cannabinoid medicine permitted for patient use by the FDA. There are other studies into its impact on OSA and Impression alluded to these in the announcement.

If the efficacy has been positive in those trials then what is the probability that the IHL clinical trials will be positive?

IHL are building on this body of work with their own proprietary formula which includes dronabinol. BOT are doing the exact same thing with their BTX1308 formula. There are other studies treating psoriasis with synthetic CBD that pre-date the trials completed by BOT.

Four separate clinical trials for IHL targeting four different market segments. $25 million MC.